CN100379723C - 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙 - Google Patents

阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙 Download PDF

Info

Publication number
CN100379723C
CN100379723C CNB038040913A CN03804091A CN100379723C CN 100379723 C CN100379723 C CN 100379723C CN B038040913 A CNB038040913 A CN B038040913A CN 03804091 A CN03804091 A CN 03804091A CN 100379723 C CN100379723 C CN 100379723C
Authority
CN
China
Prior art keywords
calcium
organic solvent
atorvastatin hemi
crystalline
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038040913A
Other languages
English (en)
Chinese (zh)
Other versions
CN1633439A (zh
Inventor
J·阿伦希姆
D·麦丹-哈诺克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN1633439A publication Critical patent/CN1633439A/zh
Application granted granted Critical
Publication of CN100379723C publication Critical patent/CN100379723C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/04—Calcium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB038040913A 2002-02-19 2003-02-19 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙 Expired - Fee Related CN100379723C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35849702P 2002-02-19 2002-02-19
US60/358,497 2002-02-19

Publications (2)

Publication Number Publication Date
CN1633439A CN1633439A (zh) 2005-06-29
CN100379723C true CN100379723C (zh) 2008-04-09

Family

ID=27757749

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038040913A Expired - Fee Related CN100379723C (zh) 2002-02-19 2003-02-19 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙

Country Status (15)

Country Link
US (2) US7122681B2 (cg-RX-API-DMAC7.html)
EP (1) EP1465901A4 (cg-RX-API-DMAC7.html)
JP (4) JP4422488B2 (cg-RX-API-DMAC7.html)
KR (3) KR20090045419A (cg-RX-API-DMAC7.html)
CN (1) CN100379723C (cg-RX-API-DMAC7.html)
AU (1) AU2003213171A1 (cg-RX-API-DMAC7.html)
CA (1) CA2475123A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20040767A2 (cg-RX-API-DMAC7.html)
IL (1) IL163594A0 (cg-RX-API-DMAC7.html)
IS (1) IS7407A (cg-RX-API-DMAC7.html)
MX (1) MXPA04007995A (cg-RX-API-DMAC7.html)
NO (1) NO20043829L (cg-RX-API-DMAC7.html)
PL (1) PL372241A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003070665A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200406229B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
CN1997651B (zh) * 2004-07-16 2012-06-06 力奇制药公司 阿托伐他汀钙的氧化降解产物
CN101027282A (zh) * 2004-07-22 2007-08-29 特瓦制药工业有限公司 阿托伐他汀半钙的新晶形及其制备方法
MX2007002248A (es) * 2004-08-25 2008-10-02 Pfizer Triazolobenzodiazepinas y su uso como antagonistas de vasopresina.
US20080009540A1 (en) * 2004-09-30 2008-01-10 Srinivasulu Gudipati Amorphous Atorvastatin Calcium
EP1868993B1 (en) * 2005-04-08 2014-04-30 EGIS Gyógyszergyár Nyilvánosan Müködõ Részvénytársaság Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form
KR20080007561A (ko) * 2005-12-13 2008-01-22 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IT1390848B1 (it) * 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN107108601B (zh) 2014-08-28 2021-08-20 阿森纽荣股份公司 糖苷酶抑制剂
US11261183B2 (en) * 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
WO2017144637A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Acid addition salts of piperazine derivatives
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
JOP20190262B1 (ar) 2017-05-23 2023-09-17 H Lundbeck As مثبطات بيرازول magl
ES2954474T3 (es) 2018-08-22 2023-11-22 Asceneuron Sa Sales de adición de ácido de succinato y fumarato de derivados de piperazina útiles como inhibidores de glucosidasa

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1190957A (zh) * 1995-07-17 1998-08-19 沃尼尔·朗伯公司 (R－(R*，R*)－2－(4－氟苯基)－β－δ－二羟基－5－(1－甲基－乙基)－3－苯基－4－[(苯基氨基)羰基]－1H－吡咯－1－庚酸半钙盐的Ⅲ型结晶

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US444129A (en) * 1891-01-06 Henry l
US4444129A (en) 1982-11-05 1984-04-24 Lecorp Method of drying fine coal particles
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
JPS59167676A (ja) 1983-03-11 1984-09-21 株式会社　大川原製作所 多室型流動層乾燥機
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
CN1087288C (zh) * 1995-07-17 2002-07-10 沃尼尔·朗伯公司 结晶[R－(R*,R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯氨基)羰基]－1H－吡咯－1－庚酸半钙盐
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
EP1535613B1 (en) 1999-11-17 2010-08-25 Teva Pharmaceutical Industries, Ltd. Process for preparing a polymorphic form of atorvastatin calcium
ATE309985T1 (de) 1999-12-17 2005-12-15 Pfizer Science & Tech Ltd Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form
AU780247B2 (en) 1999-12-17 2005-03-10 Pfizer Science And Technology Ireland Limited A process for producing crystalline atorvastatin calcium
IL155734A0 (en) * 2000-11-03 2003-11-23 Teve Pharmaceutical Ind Ltd Atorvastatin hemi-calcium form vii
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ES2319870T3 (es) 2000-12-27 2009-05-14 Teva Pharmaceutical Industries Limited Formas cristalinas de atorvastatina.
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
IN190564B (cg-RX-API-DMAC7.html) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
EE200300597A (et) * 2001-06-29 2004-02-16 Warner-Lambert Company Llc [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[fenüülamino)karbonüül]-1H-pürrool-1-hepta anhappe kaltsiumsoola (2:1) (atorvastatiini) kristallilised vormid
CZ2004126A3 (cs) 2001-07-30 2004-12-15 Dr. Reddy's Laboratories Limited Krystalické formy VI. A VII. vápenaté soli atorvastatinu
WO2003018547A2 (en) 2001-08-31 2003-03-06 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
CA2475864A1 (en) 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1190957A (zh) * 1995-07-17 1998-08-19 沃尼尔·朗伯公司 (R－(R*，R*)－2－(4－氟苯基)－β－δ－二羟基－5－(1－甲基－乙基)－3－苯基－4－[(苯基氨基)羰基]－1H－吡咯－1－庚酸半钙盐的Ⅲ型结晶

Also Published As

Publication number Publication date
JP2005523285A (ja) 2005-08-04
US7122681B2 (en) 2006-10-17
US20070027328A1 (en) 2007-02-01
NO20043829L (no) 2004-09-13
IS7407A (is) 2004-08-17
CN1633439A (zh) 2005-06-29
ZA200406229B (en) 2006-06-28
JP2009235100A (ja) 2009-10-15
EP1465901A4 (en) 2006-02-01
JP2013136630A (ja) 2013-07-11
KR20090045419A (ko) 2009-05-07
KR20040086397A (ko) 2004-10-08
WO2003070665A2 (en) 2003-08-28
WO2003070665A3 (en) 2004-02-12
MXPA04007995A (es) 2004-11-26
HRP20040767A2 (en) 2004-12-31
PL372241A1 (en) 2005-07-11
IL163594A0 (en) 2005-12-18
JP2009143957A (ja) 2009-07-02
CA2475123A1 (en) 2003-08-28
US20030216584A1 (en) 2003-11-20
EP1465901A2 (en) 2004-10-13
KR20090045420A (ko) 2009-05-07
AU2003213171A1 (en) 2003-09-09
JP4422488B2 (ja) 2010-02-24

Similar Documents

Publication Publication Date Title
CN100379723C (zh) 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙
JP5366163B2 (ja) ピタバスタチンカルシウムの新規な結晶質形態
JP2006514108A (ja) パントプラゾールナトリウムの固体状態、それらの調製方法、及び公知のパントプラゾールナトリウム水和物の調製方法
JP2009235083A (ja) アトルバスタチンヘミカルシウムの新規結晶形態およびその調製方法ならびにアトルバスタチンヘミカルシウム形態ｉ、ｖｉｉｉおよびｉｘの新規調製方法
JP2007526251A (ja) エゼチミベ多形体
JP2007514000A (ja) テガセロッド塩基及びその塩の多形現象形
WO2019094409A1 (en) Salts and solid state forms of ozanimod
EP3867264A1 (en) Solid state forms of voclosporin
US20100260851A1 (en) Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
WO2020264486A1 (en) Solid state forms of roluperidone and salts thereof
US20080139623A1 (en) Amorphous and crystalline forms of pantoprazole magnesium salt
JP2023506025A (ja) レンボレキサントの固体形態
WO2024254480A2 (en) Solid state forms of rencofilstat
WO2007038677A2 (en) Methods for preparation of ladostigil tartrate crystalline form a1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080409

Termination date: 20100219